Connecting you to perspectives from around the world
Playlist
In Focus: PRIVATE CREDIT
Will Private Credit Be a Friend or Rival of the Banks?
Private credit has become one of the fastest-growing segments of global finance, raising an important question in Thailand: Will private credit compete with banks or strengthen the financial system by complementing them? While headlines sometimes portray the two as rivals, global experience points to a different reality. Banks remain the…
Read more
How Does Private Credit Work Behind the Scenes? – The Art of Structuring
Private credit is rewriting the rules of corporate finance. What was once a niche alternative has become the preferred source of fast, flexible capital for companies facing complex or time-critical need-filling gaps that traditional lenders, constrained by regulation and risk limits, cannot immediately serve. Yet beneath the speed, flexibility and…
Read more
The Hidden Risk Factors in Private Credit – What Investors Must Understand
Private credit has quickly expanded from a niche strategy into a core allocation for global investors. The asset class offers stable income, negotiated protection and senior ranking in a borrower’s capital structure. But as private credit becomes more widely adopted in Thailand, one message is critical: this is not a…
Read more
Who Is Driving the Demand for Private Credit?
Global demand for private credit continues to accelerate, supported by long-term commitments from pension funds, insurers, sovereign wealth funds and the world’s wealthiest families. This momentum is not a short-term reaction to high interest rates, but a reflection of deeper structural changes in global capital markets. As interest in private…
Read more
Is Private Credit Really in a Bubble or Thailand’s Next Big Opportunity
Private credit has rapidly expanded into a US$2.3-trillion global industry, raising questions about whether this growth represents genuine financial strength or early signs of a bubble. At the same time, interest in private credit in Thailand has increased significantly as companies search for new ways to access capital while traditional…
Read more
Investing in the global healthcare revolution
The global healthcare sector is undergoing a profound transformation, one shaped by demographic pressures, rapid technological breakthroughs and shifting economic power centres. As populations age, chronic diseases proliferate and patients demand more personalised care, governments and investors alike are recalibrating priorities. At the core of this shift are precision medicine,…
Read more
Sanofi to buy early-stage vaccine maker Vicebio for $1.15B upfront
Sanofi will acquire the London-based vaccine startup Vicebio for $1.15 billion upfront and as much as $450 million in future payments, the companies said Tuesday. The deal marks Sanofi’s fourth acquisition of the year, following the recently completed $9 billion purchase of commercial-stage drugmaker Blueprint Medicines, an Alzheimer’s pipeline expansion…
Read more
How a tailored ALS drug could help broaden rare disease therapies
In 2020, Jaci Hermstad died at age 26 from a rare and aggressive form of ALS. But her story didn’t end there. A drug that was created just for her, called Jacifusen, has since been given to others with mutations in the FUS gene, what’s known as FUS-ALS. The results in…
Read more
After long saga, 23andMe’s deal with Anne Wojcicki’s nonprofit finally closes
At long last, Anne Wojcicki has officially bought 23andMe. The co-founder and former CEO’s nonprofit, TTAM Research Institute, on Monday said it had completed the acquisition of 23andMe’s consumer genetics business and its research unit. In June, Wojcicki’s TTAM won a bid to acquire 23andMe for $305 million as part…
Read more
FDA Pathways Offer Faster Track for Oncology Drug Development
For biotech companies advancing oncology therapies, regulatory speed can be critical to achieving key milestones and getting new therapies to patients faster. In a recent interview, Josh Taylor, PhD, senior director of regulatory affairs at Allucent, discussed how biotech companies can leverage the FDA’s expedited programs—Fast Track, Breakthrough Therapy, Accelerated…
Read more
10 clinical trials to watch the rest of 2025
Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology sector a boost in another down year.
Read more
Cancer drugmaker LaNova to sell to China’s Sino Biopharm
Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to Merck and AstraZeneca.
Read more